Wells Fargo Lifts PT on Insmed Incorporated (INSM) to $130 From $119, Keeps a Buy Rating

Insmed Incorporated (NASDAQ:INSM) is one of the best strong buy healthcare stocks to buy now. Wells Fargo analyst Tiago Fauth maintained a Buy rating on Insmed Incorporated (NASDAQ:INSM) on July 22, raising the associated price target to $130 from $119.

Insmed (INSM) Soars After Raising $650 million

A biopharmaceutical research team taking notes in front of a laboratory’s microscope.

The analyst based the optimistic rating on the company’s potential, stating that it presents a favorable risk/reward scenario for investors with the upcoming approval and launch of Brenso in bronchiectasis and the anticipated clinical developments for the rest of the year.

Fauth also stated that the market opportunity is significant despite the current low expectations, especially with the CRSsNP patient population, which may potentially result in peak sales in the $3 billion range.

The firm added that management has an optimistic outlook on the clinical data, which appears to surpass the minimum required efficacy, further supporting the optimistic rating on Insmed Incorporated (NASDAQ:INSM).

Insmed Incorporated (NASDAQ:INSM) is a global biopharmaceutical company that develops and commercializes therapies for patients with rare diseases. The company focuses on the Brensocatib and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline.

While we acknowledge the potential of INSM to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than INSM and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.